[Antimicrobial action of the combination sulfamoxole/trimethoprim in vivo (author's transl)].
The experimental infections of the mouse by gram-positive and gram-negative germs are effectively treated with the combination of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol). The potentiating effect of both substances is demonstrated by the calculated index of the synergistic effect. The therapeutic efficacy of the combination sulfamoxole/trimethoprim is proved by two models of experimental urinary infections in the rat. In the malaria of chicken and mice a notable therapeutic success is observed.
D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy; D002645:Chickens; D003556:Cystitis / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D008288:Malaria / Q000188:drug therapy; D008289:Malaria, Avian / Q000188:drug therapy; D008297:Male; D051379:Mice; D010962:Plasmodium berghei; D011704:Pyelonephritis / Q000188:drug therapy; D051381:Rats; D013423:Sulfamoxole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*
D004338:Drug Combinations; D014295:Trimethoprim; D013423:Sulfamoxole
Antimikrobielle Wirkung der Kombination Sulfamoxol/Trimethoprim (CN 3123) in vivo